lercanidipine has been researched along with Metabolic Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruno, RM; Cartoni, G; Ferri, C; Ghiadoni, L; Grassi, D; Magagna, A; Stea, F; Taddei, S; Virdis, A | 1 |
| Barrios, V; Calderón, A; de la Figuera, M; Escobar, C; Honorato, J; Llisterri, JL; Segura, J | 1 |
2 trial(s) available for lercanidipine and Metabolic Syndrome
| Article | Year |
|---|---|
Combination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Therapy, Combination; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Italy; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Treatment Outcome; Vascular Stiffness | 2017 |
High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Cross-Sectional Studies; Dihydropyridines; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Nifedipine | 2008 |